Reproxalap

Reproxalap (ADX-102) is an active aldehyde sequestering agent. Reproxalap reduces the PKCα activity. Reproxalap blocks caspase 3/7 activation. Reproxalap protects cells from the cytotoxicity of C18:0-al. Reproxalap has anti-inflammatory and pain-relieving effects. Reproxalap is used in studies of dry eye, allergic conjunctivitis, and non-infectious anterior uveitis[1][2][3][4][5].

Product Specifications

CAS Number

[916056-79-6]

Product Name Alternative

ADX-102; NS-2

UNSPSC

12352005

Hazard Statement

H303, H313, H315, H319, H333, H335

Target

Caspase; PKC

Type

Reference compound

Related Pathways

Apoptosis; Epigenetics; TGF-beta/Smad

Applications

COVID-19-immunoregulation

Field of Research

Inflammation/Immunology; Neurological Disease

Assay Protocol

https://www.medchemexpress.com/reproxalap.html

Purity

98.49

Solubility

DMSO : 100 mg/mL (ultrasonic)

Smiles

CC(C1=NC2=C(C=C(Cl)C=C2)C=C1N)(O)C

Molecular Formula

C12H13ClN2O

Molecular Weight

236.70

Precautions

H303, H313, H315, H319, H333, H335

References & Citations

[1]Susan Macdonald, et al. ADX-102, a novel aldehyde trap, reduces nociceptive behavior in mouse models of carrageenan and CFA induced pain.|[2]Reproxalap Phase 2b Dry Eye Disease Results.|[3]Susan G. Macdonald, Ph.D., et al. Novel Small Molecule Aldehyde Sequestering Agents Demonstrate Broad Therapeutic Potential for Ocular Inflammation.|[4]Ochoa CA, et al. Aldehyde Trapping by ADX-102 Is Protective against Cigarette Smoke and Alcohol Mediated Lung Cell Injury. Biomolecules. 2022 Mar 2;12 (3) :393.|[5]Rizzo WB, et al. Sjögren-Larsson syndrome: A biochemical rationale for using aldehyde-reactive therapeutic agents. Mol Genet Metab Rep. 2021 Dec 23;30:100839.